“Clinical trials such as this help us provide the best possible care and hope for our patients,” said Dr. Glen Goss. “I want to thank all the patients at our hospital who participated in this research, and all the clinical and research staff who make clinical trials possible.”The Ottawa Hospital played a key role in an international clinical trial that is providing new hope for people with advanced non-small cell lung cancer (NSCLC). The clinical trial tested four targeted therapy combinations in 268 patients whose tumours were resistant to immunotherapy.
The optimal combination involved the targeted therapy, ceralasertib, (an inhibitor of the ATR protein) along with durvalumab (an immune checkpoint inhibitor). Patients who received this combination had an objective tumour response rate of 14 per cent compared to just 2.6 per cent with other combinations. These patients also experienced a significant survival benefit with manageable side effects.
“Clinical trials such as this help us provide the best possible care and hope for our patients,” said The Ottawa Hospital’s Dr. Glen Goss, who played a key role in developing the trial. “I want to thank all the patients at our hospital who participated in this research, and all the clinical and research staff who make clinical trials possible.”
See the full paper in Nature Medicine and the media release from the lead centre, MD Anderson Cancer Centre.
Authors: Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, Awad MM, Thomas M, Goss G, Wheatley-Price P, Shepherd FA, Florescu M, Cheema P, Chu QSC, Kim SW, Morgensztern D, Johnson ML, Cousin S, Kim DW, Moskovitz MT, Vicente D, Aronson B, Hobson R, Ambrose HJ, Khosla S, Reddy A, Russell DL, Keddar MR, Conway JP, Barrett JC, Dean E, Kumar R, Dressman M, Jewsbury PJ, Iyer S, Barry ST, Cosaert J, Heymach JV.
Funding: AstraZeneca
The Ottawa Hospital is a leading academic health, research and learning hospital proudly affiliated with the University of Ottawa and supported by The Ottawa Hospital Foundation.
